Skip to Main Content

Paper Details

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
0
2023
DNA damage response genes, HRR, HRR gene, HRR-deficient, Patients, androgen, androgen receptor, anemia, enzalutamide, fatigue, mCRPC, metastatic castration-resistant prostate cancer, neutropenia, patients, poly(ADP-ribose), poly(ADP-ribose) polymerase, prostate cancer, prostate cancer cells, talazoparib
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute (NCI-CCC), University of Utah
  • 1 - 1

Datasets

Release 1.2